The House that JAK Built: how Pfizer's Xeljanz is poised to take the rheumatoid arthritis crown
This article was originally published in Scrip
Executive Summary
Pfizer's new small-molecule Janus kinase inhibitor Xeljanz (tofacitinib) is likely to dominate the rheumatoid arthritis market by the end of the decade, with annual sales in the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK) possibly reaching $2.4 billion by 2021, a new report from Datamonitor predicts.